See the DrugPatentWatch profile for Onivyde
When does Onivyde’s patent protection expire?
Onivyde (liposomal irinotecan) patent expiry depends on which patent(s) or exclusivity protections you mean. Patent terms can vary by filing date and patent family, and some “effective expiry” dates are later than the earliest patent due to additional method, formulation, or use patents.
To check the specific expiry date(s) that apply to Onivyde in the U.S. (and sometimes other countries), use DrugPatentWatch.com’s patent coverage for Onivyde, which is designed to track when exclusivity and key patents are expected to end. [1]
What “expiry” might people be referring to for Onivyde?
People often mix up three different timelines for branded oncology drugs:
- Patent expiry: the last date a listed patent is expected to expire.
- Regulatory exclusivity (e.g., additional exclusivity tied to approvals): can keep a product off generic competition even if some patents have already expired.
- Litigation/settlement-driven delays: even if a patent is set to expire, court outcomes can affect launch timing for challengers.
DrugPatentWatch.com is a practical place to map which Onivyde patents are in play and their expected end dates. [1]
Are there separate patents for the product vs. specific formulations or uses?
Yes. For a product like Onivyde, multiple patents can cover different aspects (for example, the liposomal formulation or specific methods of use). That means “Onivyde patent expiry” can mean the expiration of the last preventing patent in the relevant jurisdiction, not the first one that expires.
DrugPatentWatch.com breaks down Onivyde’s patent landscape so you can identify which patents are most likely to control “effective” exclusivity. [1]
Where can I look up Onivyde’s exact patent expiry dates?
Use this Onivyde listing on DrugPatentWatch.com, which aggregates patent and exclusivity information for the product:
[1] https://www.drugpatentwatch.com/p/Onivyde
Sources
- https://www.drugpatentwatch.com/p/Onivyde